SCHEMBL15540801

SCHEMBL15540801

N#Cc1n[nH]c2ccc(Cl)cc12

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.45
HTR2A P28223 1/20 0.42
NTRK1 P04629 2/20 0.41
ERBB2 P04626 1/20 0.41
JAK2 O60674 1/20 0.41
PSMB8 P28062 1/20 0.40
ABCC9 O60706 1/20 0.39
DYRK1A Q13627 1/20 0.39
NTRK3 Q16288 1/20 0.38
NOS1 P29475 1/20 0.38
LRRK2 Q5S007 1/20 0.38
CYP2A6 P11509 1/20 0.38
USP8 P40818 2/20 0.37
USP7 Q93009 2/20 0.37
USP47 Q96K76 1/20 0.37
CHEK1 O14757 1/20 0.37
CHUK O15111 1/20 0.37
MCHR1 Q99705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9980415 0.86 MAP2K4 (0.44) FADS1ERBB2PSMB8DYRK1ANOS1
SCHEMBL31621168 0.86 MAP2K4 (0.44) FADS1ERBB2PSMB8DYRK1ANOS1
SCHEMBL4008602 0.79 GSK3B (0.51) HTR2ANTRK1JAK2NTRK3LRRK2
SCHEMBL15541661 0.79 NTRK1 (0.56) FADS1HTR2ANTRK1ERBB2DYRK1A
SCHEMBL14818880 0.79 MAP2K4 (0.49) FADS1NTRK1ERBB2LRRK2
SCHEMBL1758957 0.79 PDPK1 (0.58) FADS1HTR2ANTRK1ERBB2JAK2
SCHEMBL16431805 0.78 NTRK1 (0.42) NTRK1JAK2NTRK3LRRK2
SCHEMBL11753886 0.75 FADS1 (0.42) FADS1HTR2AJAK2PSMB8ABCC9
SCHEMBL17221540 0.75 NTRK1 (0.50) FADS1HTR2ANTRK1DYRK1ALRRK2
SCHEMBL13554441 0.75 NTRK1 (0.44) NTRK1NTRK3LRRK2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 US disclosed
EP-3925956-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2024-04-10 EP disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-11559515-B2 Indole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2023-01-24 US disclosed
US-11559515-B2 Indole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2023-01-24 US disclosed
CN-115490751-A Factor D inhibitors 拜奥克里斯特制药公司 2022-12-20 CN disclosed
CN-109121414-B Benzopyrazole compounds and analogs thereof 拜奥克里斯特制药公司 2022-07-05 CN disclosed
EP-3411411-B3 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2022-01-26 EP disclosed
US-20160185759-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-06-30 US disclosed
EP-3027605-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2016-06-08 EP disclosed
US-20150190457-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2015-07-09 US disclosed
US-20150141455-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2015-05-21 US disclosed
EP-2867226-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF Novartis AG (CH) 2015-05-06 EP disclosed
EP-2867225-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS Novartis AG (CH) 2015-05-06 EP disclosed
WO-2015015519-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-02-05 WO disclosed
WO-2015015519-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-02-05 WO disclosed
WO-2014002051-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2014-01-03 WO disclosed
WO-2014002054-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS NOVARTIS AG (CH) 2014-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185759-A1 NOVEL INDAZOLE COMPOUNDS AND A PROCESS FOR THE PREPARATION THEREOF GPR119, INSR, CYP11B1 FADS1 1390/4885HTR2A 4135/4885NTRK1 4855/4885
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 FADS1 3795/4885HTR2A 3624/4885NTRK1 3941/4885
US-20150141455-A1 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF C5, C3AR1, C9 FADS1 2527/4885HTR2A 1704/4885NTRK1 3612/4885
US-20150190457-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS C5, C9, TFPI FADS1 4179/4885HTR2A 2045/4885NTRK1 3410/4885
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF C9, C5, C1QBP FADS1 3361/4885HTR2A 3486/4885NTRK1 4393/4885
US-11559515-B2 Indole compounds and analogues thereof C5, IDO1, IDO2 FADS1 1720/4885HTR2A 66/4885NTRK1 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.